Perfil epidemiológico de pacientes com hemofilia A e doenças associadas ao uso do fator VIII Recombinante
Carregando...
Arquivos
Data
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade do Estado do Amazonas
Resumo
In Brazil, registered in the Ministry of Health, 12.983 patients with
Hemophilia A. The diagnosis is based on clinical findings, laboratory tests and
differential diagnosis. Treatment is to infuse the missing clotting factor. Reactions to the
use of the factor can include, allergic manifestations, transfusion viral diseases and about
30% of patients develop alloantibodies. Preventive measures must be carried out with a
view to improving health, quality of life and patient compliance with treatment and
reducing exposure to a high number of doses of the factor. Objective: Characterize the
epidemiological profile of patients with Hemophilia A, investigating diseases associated
with the use of factor VIII and recombinant factor VIII at the Hospital Foundation of
Hematology and Hemotherapy of Amazonas. Method: Epidemiological, cross-sectional,
retrospective and documentary study. Inclusion criteria: Medical record of patients
diagnosed with hemophilia A, filled with more than 70% of the information. CAAE:
11986918.6.0000.0009. Results: Registered with the Ministry of Health, a quantitative
of 276 individuals diagnosed with Hemophilia A, in Amazonas. 164 medical records
included for analysis of this study. Sociodemographic characteristics: male gender,
99,4%, prevalence of adolescents (28%) and young people (26,8%), brown race, 67,1%,
incomplete elementary school, 28,6%, occupation: student, 42,7%. Clinical condition:
36,6% classified with severe hemophilia A. All with diagnoses, clinical and laboratory.
The most common degree of kinship was that of brothers, 35,3%. Predominant
symptoms: hemarthrosis (70 / 45,4%), pain (49 / 31,9%), edema (37 / 24%) and
arthropathy (13 / 8,5%). Recombinant factor VIII, administered to 57 (34,8%) patients,
while plasma factor VIII to 46 (28,0%), with doses ranging from 2000 IU to 2999 IU.
Complications: arthralgia (77,4%) and hemorrhage (77,4%). Conclusions: Good quality
care by health professionals helps to prevent serious complications, resulting in quality
of life for the hemophiliac